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ABSTRACT: This paper reports the detection of the inflammatory and sepsis-
related biomarker, interleukin-6 (IL-6), in human blood plasma using
functionalized screen-printed electrodes (SPEs) in conjunction with a thermal
detection methodology, termed heat-transfer method (HTM). SPEs are
functionalized with antibodies specific for IL-6 through electrodeposition of a
diazonium linking group and N′-ethylcarbodiimide hydrochloride (EDC)
coupling, which was tracked through the use of cyclic voltammetry and Raman
spectroscopy. The functionalized SPEs are mounted inside an additively
manufactured flow cell and connected to the HTM device. We demonstrate
the ability to detect IL-6 at clinically relevant concentrations in PBS buffer (pH =
7.4) with no significant interference from the similarly sized sepsis-related
biomarker procalcitonin (PCT). The limit of detection (3σ) of the system is
calculated to correspond to 3.4 ± 0.2 pg mL−1 with a working range spanning the
physiologically relevant concentration levels in both healthy individuals and patients with sepsis, indicating the sensitivity of the
sensor is suitable for the application. Further experiments helped provide a proof-of-application through the detection of IL-6 in
blood plasma with no significant interference observed from PCT or the constituents of the medium. Due to the selectivity,
sensitivity, straightforward operation, and low cost of production, this sensor platform has the potential for use as a traffic light sensor
for the multidetection of inflammatory biomarkers for the diagnosis of sepsis and other conditions in which the rapid testing of
blood biomarkers has vital clinical application.
■ INTRODUCTION
The United Nations World Health Assembly has recognized
sepsis as a global health priority with more than 19 million
sepsis cases and 6 million annual sepsis-related deaths
estimated to occur worldwide.1 It has been reported that, for
every hour that sepsis remains undiagnosed in a patient and
treatment is not initiated, there is a 7.6% reduction in patient
survival rate,2 and hence, it is considered a medical emergency.
Sepsis is defined as life-threatening organ dysfunction due to a
dysregulated host response to infection.3 The infectious agent
is the instigator, while the host’s overexaggerated (hyper-
inflammatory) immune system is responsible for the wide-
spread organ damage that is characteristic of the condition.
Hence, current absolute diagnosis requires the evidence of a
bloodstream infection (BSI) as well as indicators of systemic
inflammation. A heightened understanding of the inflammatory
processes that lead to host tissue damage in sepsis has led to
the identification of several key biomarkers that allow for
improved risk stratification and treatment decision making;
These include biomarkers involved in the hyper-inflammatory
“cytokine storm” and acute phase response. Indeed, there is
considerable evidence demonstrating interleukin-6 (IL-6) in
particular as a useful diagnostic and prognostic marker.4
Interestingly, the importance of IL-6 in the progression of
severe respiratory illness and multiorgan failure in COVID-19
patients has recently been highlighted. Critically ill COVID-19
patients, by definition, have sepsis; they present with infection
in the presence of organ dysfunction. Higher concentrations of
this cytokine in COVID-19 patients are associated with more
profound host tissue damage, progression to mechanical
ventilation, and ultimately death.5 Further, the blockade of
IL-6 has been suggested as a potential treatment approach for
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critically ill COVID-19 patients,6 although the results from
randomized controlled clinical trials are awaited.7
Current testing methods for sepsis involve lengthy
laboratory procedures for the detection of a BSI and also
inflammatory markers with in vitro blood culture testing often
taking up to 72 h. Diagnosis is therefore often made on the
basis of clinical judgment in the absence of laboratory results.
It is clear that more rapid testing methods need to be
developed. Approaches to overcome these lengthy turnaround
times include multi-ELISA arrays8 and optical9 and electro-
chemical detection10 of biomarkers. The vast majority of the
systems reported in the literature utilize specific antibodies as
their recognition element, where the interaction between the
target protein and the antibodies can be determined using a
wide array of detection methods. For electrochemical
detection, one way of immobilizing these antibodies onto the
surface of an electrode is through carbodiimide-mediated
coupling,11 which involves the formation of an amide bond
between either a carboxyl or amine group on the antibody and
the counter group on the surface. The modification of the
electrodes with moieties containing these functional groups
can be achieved simply through the electrografting of
diazonium salts. This involves the irreversible one electron
reduction of the diazonium salt and the formation of a covalent
bond between it and the surface of the electrode. This has been
shown for various electrode materials such as gold12 and
carbon.13 Using screen-printed electrodes (SPEs) is advanta-
geous over other electrode materials due to their high
reproducibility, low cost, and suitability for mass production.14
The electrografting of diazonium salts onto SPEs and coupling
antibodies for the purpose of electrochemical biosensor
production are well explored research areas.15 However,
there have been no reports in the literature of this
methodology used in conjunction with thermal detection.
The heat-transfer method (HTM) is a thermal detection
method that utilizes the heat-transfer resistance at the solid−
liquid interface. Its first use for medical diagnostics was
described in 201216 for the monitoring of mutations in DNA.
This method has the advantage of low cost and label free
analysis, which synergizes well with the use of SPEs. The HTM
has since been used for the detection of small molecules17 and
proteins18 as well as monitoring bacteria19 with an emphasis on
its use in conjunction with molecularly imprinted polymers
(MIPs) due to the large amounts of cavities provided. There
have been no attempts to utilize antibodies for a biosensing
platform alongside the HTM reported in the literature, most
likely due to the smaller surface coverage. Improvements to the
measurement design have allowed for improved specificity,
leading to the ability to detect antigen−antibody interactions.
This work presented herein reports the possibility to open up
completely new fields of research for the HTM and thermal
detection due to the vast array of uses for antibodies and the
adaptability of the proposed sensing platform.
Consequently, in this paper, we present the first report of
antibody-based biorecognition in conjunction with the HTM
for the label-free detection of the inflammatory marker IL-6 in
blood plasma. The SPEs are functionalized through electro-
grafting a suitable carboxyphenyl film onto the surface via the
reduction of a diazonium salt, followed by the antibody
immobilization through the N′-ethylcarbodiimide hydrochlor-
ide (EDC)/N-hydroxysuccinimide (NHS) coupling process.
These functionalized electrodes are then used for the detection
of IL-6 in conjunction with the HTM in both buffered
solutions and, more importantly, human plasma. The
successful measurement of IL-6 in clinically relevant ranges,
using a small sample size (∼100 μL) and in under 45 min
(which could be reduced further through optimization of the
baseline measurements and an injection procedure20), indicate
its promise for a point-of-care testing system that could lead to
dramatic decreases in sepsis-related mortality. This study
shows the potential for the widespread use of this technology,
in research and practice, due to its low cost of production and
through the ability to monitor antigen−antibody interactions
in real-time.
■ EXPERIMENTAL SECTION
Materials and Instruments. All chemicals were purchased
and used without further purification. Sodium nitrite, 4-
aminobenzoic acid, N-(3-(dimethylamino)propyl)-N′-ethyl-
carbodiimide hydrochloride (EDC), N-hydroxysuccinimide
(NHS), bovine serum albumin (BSA), Tween 20, and
potassium ferrocyanide were obtained from Merck Life Science
UK Limited (Gillingham, United Kingdom). Hydrochloric
acid was purchased from Fisher Scientific (Loughborough,
United Kingdom). Recombinant human interleukin-6 (IL-6)
protein (200-06) and anti-human IL-6 antibodies (500-M06)
were purchased from PeproTech EC Ltd. (London, United
Kingdom). Procalcitonin (PCT) was purchased from Abcam
PLC (Cambridge, United Kingdom). Phosphate buffered
saline (PBS) solutions were prepared using PBS tablets
purchased from Merck Life Science UK Limited (Gillingham,
United Kingdom) and deionized water of resistivity not less
than 18.2 MΩ cm. Human blood plasma was purchased from
the NHS Blood & Transplant Service (NHSBT), therefore
alleviating the need for HRA approval. The plasma was
obtained as fresh frozen plasma (FFP) and was defrosted at
room temperature prior to use in the experiments. All FFP
used was Group O RhD positive. Raman spectroscopy was
performed on a Renishaw PLC in Via Raman microscope
controlled by WiRE 2 software at a laser wavelength of 514
nm.
Electrochemical Measurements. All electrochemical
experiments were performed in solutions purged with highly
pure nitrogen at 20 ± 1 °C on a Metrohm AG Autolab
PGSTAT101 (Utrecht, The Netherlands) controlled by
NOVA 2.0. All measurements were conducted using screen-
printed electrodes (SPEs; Manchester Metropolitan Univer-
sity).21 Briefly, the SPEs were fabricated in-house using a
stencil design to achieve a 3.1 mm diameter working electrode
using graphite ink (Product Ink: C2000802P2; Gwent
Electronic Materials Ltd., Pontypool, United Kingdom) and
were printed using a DEK 248 screen printer machine (DEK,
Weymouth, United Kingdom) onto a polyester flexible film
(250 μm thickness; Autostat, Milan, Italy). The layer was
cured in a fan oven at 60 °C for 30 min. Next, a silver/silver
chloride reference electrode was introduced by screen-printing
Ag|AgCl paste (Product Code: D2070423D5; Gwent Elec-
tronic Materials Ltd., Pontypool, United Kingdom) onto the
polyester substrates and cured in a fan oven for 30 min at 60
°C. Finally, a dielectric paste (Product Code: D2070423D5;
Gwent Electronic Materials Ltd., Pontypool, United Kingdom)
was then printed onto the polyester substrate to cover the
connections and cured for an additional 30 min at 60 °C
before use.22
Tracking and identification of the electrode modification was
performed using cyclic voltammetry in conjunction with
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[Fe(CN)6]
3−/4− as the redox probe. A solution of [Fe-
(CN)6]
3−/4− (10 mM) was prepared in KCl (0.1 M) and
degassed with pure nitrogen for 15 min. A droplet of 40 μL
was deposited onto the SPE, making sure all three electrodes
were fully covered, and cyclic voltammetry was performed at a
scan rate of 50 mV s−1 between −0.5 and +0.8 V.
Heat-Transfer Measurements. Once functionalized (see
below), SPEs were cut into 1 × 1 cm squares, inserted into an
additively manufactured (AM) flow cell,18b and sealed with an
O-ring (RS Components, Stockport, United Kingdom); see
Figure S1A. Thermal measurements were carried out using a
flow cell (Figure 2A) with an internal volume of 110 μL in
conjunction with the heat-transfer setup.16 The flow cell was
connected to a copper block that acts as a heat sink. The
temperature of the block (T1) is controlled via a proportional-
integral-derivative (PID). The PID parameters can affect the
power signal stability and therefore the sensitivity of the
developed sensor. As such, these values were set to the
optimized values determined for this heat source of P = 1, I =
14, and D = 0.3.18b A type-K thermocouple (RS Components,
Stockport, United Kingdom) is used to measure the temper-
ature of the sample solution (T2) 1.7 mm above the surface of
the SPE. The thermal resistance (Rth) at the solid−liquid
interface can be determined by dividing the measured
temperature difference between the copper block and the
solution (T1 − T2) by the power provided to the heat source to
maintain its temperature; the HTM device is presented in
Figure S1B.
For aqueous experiments, the flow cell was placed inside an
incubator (20 ± 0.02 °C, INCU-Line, VWR, Leicestershire,
United Kingdom) and was filled with PBS (pH = 7.4), and the
copper block was heated to a predetermined temperature of 37
± 0.02 °C. The cell was left to stabilize for 45 min before the
first injection in order to establish a baseline reading. Following
this, sequential 2 mL additions of IL-6 protein (5−1000 pg
mL−1) in PBS were injected into the flow cell through silicone
tubing (Fisher Scientific, Loughborough, United Kingdom)
using an automated NE500 programmable syringe pump
(Prosense, Oosterhout, The Netherlands) at a flow rate of 250
μL min−1. After each injection, the temperature of the cell was
allowed to stabilize for 30 min to establish a reading. For each
concentration, the last 10 min of each stabilization, which
corresponds to 600 data points, was averaged out and used to
calculate Rth. These experiments were carried out in triplicate
to prove the reproducibility of the results. The calculated Rth
values were used to produce dose−response curves and
mathematically calculate the limit of detection (LOD) using
the three sigma method from the linear section of the
logarithmic plot. Specificity tests were carried out by injecting
2 mL of the same concentration of the competitive target
procalcitonin (PCT). To test the system in a relevant
biological media, the flow cell was stabilized in blood plasma
and then 2 mL of IL-6 (5−1000 pg mL−1) in blood plasma was
injected into the cell. These experiments were repeated with
PCT in blood plasma.
Sensor Fabrication. The stepwise electrode preparation is
illustrated in Figure 1A. First, a diazonium layer was
electrochemically deposited onto the surface of the SPEs. A
solution of 4-aminobenzoic acid (2 mM) and sodium nitrite (2
mM) was prepared in HCl (0.5 M) and placed on a rocking
table for 10 min. A 50 μL droplet of this solution was placed
onto the surface of the SPEs, making sure all three electrodes
were fully covered. The electrodeposition of the diazonium
layer was achieved through applying 3 cyclic voltammetric
sweeps from +0.2 to −0.6 V at a scan rate of 100 mV s−1.
Subsequently, the carboxyl functionalization was activated
through incubation with a solution of EDC (100 mM) and
NHS (20 mM) in PBS buffer (pH = 5) on the working
electrode for 1 h. Next 7.5 μL of the anti-IL-6 antibody (10 μg
mL−1) in PBS (pH = 7.4) was dropped onto the working
Figure 1. (A) Schematic depicting the functionalization of a screen-printed electrode (SPE) with antibodies specific for interleukin-6. (B) Raman
spectroscopy for the functionalization of screen-printed carbon electrodes with diazonium linking groups using different amounts of scans in cyclic
voltammetry. (C) Cyclic voltammograms for [Fe(CN)6]
3−/4− (10 mM) in 0.1 M KCl after each step of the electrode functionalization procedure,
including the incubation with interleukin-6.
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electrode surface for 3 h at room temperature to immobilize
the antibodies. Finally, the electrodes were incubated with a
solution of BSA (1 wt %) in PBS (pH = 7.4) for 30 min to
mitigate any nonspecific interactions with activated carboxyl
groups and the free electrode surface. Following functionaliza-
tion, the electrodes were stored in PBS (pH = 7.4) at 4 °C
until use.
■ RESULTS AND DISCUSSION
Antibody Functionalization of the Screen-Printed
Electrodes (SPEs). The functionalization of the screen-
printed electrodes (SPEs) was achieved through a multistep
process, as summarized in Figure 1A. This involved the
electrografting of a carboxyphenyl film onto the graphite
surface of the working electrodes of the SPEs, followed by
activation of the carboxyl group through EDC/NHS coupling,
then immobilization of antibodies specific for IL-6, and finally,
blocking of the free surface with BSA. The electrografting of
the carboxyphenyl group onto the graphite surface of the SPEs
was achieved through the electrochemical reduction of a
diazonium salt using cyclic voltammetry cycled between +0.2
and −0.6 V at 100 mV s−1. The cyclic voltammograms
exhibited the characteristic irreversible peak between −0.2 and
−0.3 V for the one electron reduction of the carboxyphenyl
diazonium salt, followed by the decrease in peak current
intensity for the subsequent scans. This decrease is attributed
to the increase of carboxyphenyl groups covalently attached to
the surface of the electrode that leads to a decrease in the
electron transfer efficiency between the diazonium salt and the
electrode surface.23 This process was performed for different
numbers of scans and analyzed through Raman spectroscopy,
Figure 1B, to track the formation of the carboxyphenyl film on
the surface of the working electrode. The bare SPEs exhibited
the characteristic behavior with a D and G peak observed,
associated with the sp3 defects and sp2 hybridized carbon
vibrations, respectively.24 The enhancement of the D peak
observed in the Raman spectrum after the electrografting
procedure indicates the increase in sp3 carbons on the surface
due to the formation of C−C sp3 bonds after carboxyphenyl
covalent attachment.25 Following three cyclic voltammetric
scans, the reduction peak of the diazonium salt was suitably
reduced to indicate the partial blocking of the surface by the
carboxyphenyl film. Following this, the antibody was
immobilized onto the film through the activation of the
carboxylic acid groups via EDC/NHS coupling. After this
coupling process, the cyclic voltammetric peak for [Fe-
(CN)6]
3−/4− exhibited an increase in the current intensity
attributed to the neutralization of a negatively charged carboxyl
group on the surface.26 After confirmation of the covalent
attachment of the antibody to the working electrode surface
was obtained, the electrode was incubated in 10 pg mL−1 IL-6
target protein to observe any response using cyclic
voltammetry. There was a small observed decrease in the
[Fe(CN)6]
3−/4− peak current intensity, indicating the binding
of the protein to the antibody on the SPE surface, and a
subsequent increase in the resistance to electron transport.
Once proof of modification was obtained, the functionalized
SPE was tested for its response to IL-6 across a wide range of
Figure 2. (A) Schematic representation of the flow cell used for HTM measurements, consisting of a sample chamber, sample inlet and outlet, and
a thermocouple slot. (B) Raw HTM data plot for the addition of IL-6 (5−1000 pg/mL) in PBS to an electrode functionalized with IL-6 antibodies.
(C) Dose response curves for the percentage change in the measured thermal resistance (Rth) for the addition of IL-6 (red) and PCT (blue) in PBS
to an electrode functionalized with IL-6 antibodies. Note that, due to the HTM, occasionally, air bubbles can affect the measurements (see panel B)
due to the physical constraints of the flow cell (see panel A).
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relevant concentrations in conjunction using a thermal
detection methodology via the use of the HTM.
Thermal Detection of IL-6. In order to check the viability
of the modified SPEs and sensor platform for the detection of
the sepsis biomarker IL-6, initial experiments were performed
using solutions of IL-6 in PBS (pH = 7.4). The antibody
modified electrodes were cut down to a 1 × 1 cm square
around the working electrode and mounted inside an AM flow
cell, Figure 2A, using an O-ring and copper block. The copper
block was set to a temperature of 37.00 ± 0.02 °C, which was
maintained throughout the measurements. First, the cell was
filled with a blank solution of PBS an allowed to equilibrate for
45 min to establish a baseline reading and all readings were
taken from an average of the final 10 min of each concentration
(corresponding to 600 data points). As can be observed in the
raw data plot in Figure 2B, there is a large spike in the baseline
reading that corresponds to the removal of air bubble in the
cell. Air bubbles can inflate the Rth values and cause a drift
upward, which can be observed in the values just before air
removal. Following this, a stable baseline is obtained from
which to measure. Following the 45 min stabilization period,
an extra injection of blank PBS was added to confirm the new
baseline was accurate, and then, sequentially increasing
concentrations of IL-6 (5−1000 pg mL−1) in PBS were
introduced into the system using an automated pump at a rate
of 250 μL min−1; it was then allowed to stabilize for 30 min.
The large vertical spikes in the raw data plot seen in Figure 2B
correspond to these injections. As the solution being injected is
stored at room temperature in the syringe, there is a sharp
initial spike in the resistance as the solution is heated.
Following each injection and stabilization, the last 10 min (600
data points) of each concentration measurement is used to
calculate an average Rth measurement. In PBS, the Rth value
stabilized at a value of 2.63 ± 0.05 °C/W for the functionalized
electrode. Upon the injection of the first concentration of IL-6,
the measured Rth value increased to a value of 2.79 ± 0.04 °C/
W, which corresponded to a 6 ± 2% rise in the signal. An
increase in Rth was observed for all concentrations of IL-6
added to the flow cell, including for the highest concentration
of 1000 pg mL−1 that stabilized at a value of 3.23 ± 0.04 °C/
W, which was equivalent to a 23 ± 1% increase. These results
were used to calculate the intra-assay coefficient of variation
(%CV) of 1.3%. The work was repeated in triplicate to
produce an interassay %CV of 9%, and the results were plotted
in the form of a dose−response curve (Figure 2C), which was
used to calculate the limit of detection (LOD) of 3.4 ± 0.2 pg
mL−1, on the basis of the 3σ method using the logarithmic
linear plot of formula of y = 0.21x + 2.64 (R2 = 0.98). To show
that the change in the measured Rth is due to the specific
binding of IL-6 to the antibodies immobilized on the surface of
the electrode, experiments were conducted by injecting IL-6
(5−2000 pg mL−1) to SPEs with no antibodies (only blocked
with BSA) and to SPEs functionalized with procalcitonin
antibodies (Figures S2 and S3, respectively). No significant
change in the measured Rth was observed in either case,
indicating that there was no binding of IL-6 onto the surface of
the electrode. In addition to this, a similarly sized and relevant
protein procalcitonin (PCT) was injected into the system,
Figure 2C. In this case, the baseline Rth stabilized at a value of
3.40 ± 0.04 °C/W. For the injections of PCT, there is no
Figure 3. (A) Raw HTM data plot for the addition of IL-6 (5−1000 pg/mL) in blood plasma to an electrode functionalized with IL-6 antibodies.
(B) Plot of the change in measured thermal resistance (Rth) for the addition of IL-6 (red) and PCT (blue) in blood plasma to an electrode
functionalized with IL-6 antibodies. (C) Plot of the change in measured thermal resistance (Rth) for the addition of IL-6 in PBS (red) and blood
plasma (blue) to an SPE functionalized with IL-6 antibodies.
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significant increase in the measured Rth until the addition of 25
pg mL−1, where Rth stabilized at a value of 3.57 ± 0.1 °C/W,
corresponding to an increase of 5 ± 3%. In comparison to the
system where IL-6 was added, for 25 pg mL−1, Rth showed an
increase of 11 ± 1%. Additionally, there is a larger amount of
error observed in the PCT measurement for this concen-
tration. After this addition, Rth falls again closer to the baseline
and finally ends at an increase of 4 ± 1%. This shows that the
sensing platform is specific for the detection of IL-6.
Thermal Detection of IL-6 in Blood Plasma. To provide
proof-of-application, experiments were performed using blood
plasma as the medium spiked with IL-6 and then PCT. In this
way, blood plasma was injected into the system and allowed to
stabilize for 45 min to form a baseline, Figure 3A. Rth stabilized
at a value of 4.29 ± 0.04 °C/W, which as expected due to the
added elements in blood serum, was significantly higher than
the baseline for PBS, even when including the errors in
thermocouple absolute measurements. The complexity of the
media also accounted for the increase in the noise of the signal
and standard deviation. For the smallest injection of 5 pg mL−1
IL-6, there was no observed significant increase in the
measured Rth value, which can be due to the presence of
blood proteins (and other constituents) fouling the electrode
surface and hampering detection.18b However, when 25 pg
mL−1 IL-6 was introduced, Rth increased to a value of 4.48 ±
0.04 °C/W. This increase continued for the addition of 100 pg
mL−1 IL-6, where Rth stabilized at a value of 4.67 ± 0.04 °C/
W, indicating that it is possible to detect clinically relevant
increases in the IL-6 concentration above the normal
physiological range in blood plasma. The gradients of the
logarithmic linear plots for both PBS and blood plasma (0.21
and 0.20, respectively) compare favorably, showing an absence
of significant matrix effects. This was tested in the same way
with injections of PCT to check whether the increase in Rth
was from the buildup of matter from the blood plasma on the
surface of the electrode. As seen in Figure 3B, there was a
significantly lower increase in the measured Rth for the addition
of PCT in blood plasma. The increase in Rth for the addition of
100 pg mL−1 PCT was measured to be 0.06 °C/W. This
clearly shows that the sensing platform is specific for the
detection of IL-6 in blood plasma, can deliver results in under
15 min after sample injection, and can be applicable as a traffic
light-type sensor for increases in IL-6 concentration above
clinically relevant physiological levels. A comparison of this
methodology to others reported in the literature is presented in
Table 1. It is clearly evident from the inspection of Table 1 that
the methodology presented here performs extremely well in
comparison to other reported approaches. The vast majority of
reported sensors for IL-6 utilize expensive or complex
substrates, increasing the cost of materials or time of the
sensor manufacture. In addition, our platform can report
results in less than 15 min post sample injection, whereas most
reported sensors take an hour or longer to report results,
meaning our sensor would provide a diagnosis within the well-
established “golden hour” of sepsis.2 This work utilizes facile
coupling technology in conjunction with SPEs and a simple
read out strategy, which would massively reduce the cost of
production. Through optimization of the HTM setup into a
portable device with direct injection onto the electrode, this
system could potentially be able to report results in under 15
min after the injection of a very small sample volume (cell
volume = 110 μL).20
When compared to other instances reported in the literature
for the detection of IL-6, this work compares favorably with
the limits of detection in the biologically relevant range.4e In
addition to this, the sensor platform is shown, herein, to work
well in complex biological media, where many others cannot
demonstrate this or require extensive sample pretreatment.
This work shows that antibody functionalized SPEs can detect
IL-6 at the clinically relevant ranges for a traffic light sensor
that is giving on-the-spot results with optimization of the
device suitable for deployment in intensive care unit (ICU)
settings, which would greatly reduce patient mortality.
■ CONCLUSIONS
Screen-printed electrodes (SPEs) have been functionalized
with antibodies specific for interleukin-6 (IL-6) through
electrodeposition of a diazonium linking group and EDC/
NHS coupling. This modification was tracked and confirmed
through electrochemical and Raman techniques. The modified
SPEs were used for the detection of IL-6 in a PBS buffer
solution and in blood plasma using the heat-transfer method
(HTM). This is the first report in the literature for the use of
antibodies in conjunction with the HTM or the use of the
HTM to detect IL-6. The sensor platform was tested in PBS
buffer, where increases in the measured thermal resistance
were observed when IL-6 was introduced to the system. Dose−
response curves were constructed, which showed excellent
sensitivity for the detection of IL-6 with a LOD of 3.4 ± 0.2 pg
mL−1, which is within the physiologically relevant range. No
significant interference was observed when introducing the
Table 1. Compilation of Published Sensor Platforms for the Detection of Interleukin-6 (IL-6), Comparing Their Detection
Methodologies, Limits of Detection and Viability in Biological Media
recognition









antibodies ITOa/TiO2/CdS photoelectrochemical 60 0.38 1−100 000 no 27
antibodies ITOa/AuNPb-PDOPc amperometric 110 1.0 4−800 yes 28
antibodies Au DPVg 2.5 N/A 0−60 yes 10e
aptamer GCEd EISh 60 1.6 5−100 000 yes 29
antibodies Al2O3/nanoAu conductometric 30 5 25−400 yes 30
antibodies ELISAe ELISpot 480 39 39−2500 yes 31
antibodies Au SPRi 40 11.29 5−20 yes 32
aptamer Au/AuNPb EISh 60 0.02 0.02−200 no 33
antibodies SPEsf thermal <45 3.37 5−1000 yes present
study
aIndium tin oxide. bGold nanoparticles. cPolydopamine. dGlassy carbon electrode. eEnzyme-linked immunosorbent assay. fScreen-printed
electrodes. gDifferential pulse voltammetry. hElectrochemical impedance spectroscopy. iSurface plasmon resonance.
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sensor platform to a similarly sized protein in procalcitonin
(PCT). These tests were repeated in blood plasma and again
showed excellent sensitivity toward IL-6 and no significant
interference from the presence of PCT or other moieties in the
medium. This provided proof-of-application for the technol-
ogy, indicating the possibility for its use in a healthcare setting
as a traffic light sensor due to its clinically relevant detection
levels, fast turnaround time, low cost of production,
straightforward operation, and ability to tailor the sensor to
other targets. Additionally, the ability to detect antigen−
antibody interactions exhibits the possibility to open up
completely new fields of research for the HTM and thermal
detection due to the vast array of uses for antibodies and the
adaptability of the proposed sensing platform.
■ ASSOCIATED CONTENT
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Craig E. Banks − Faculty of Science and Engineering,
Manchester Metropolitan University, Manchester M1 5GD,
United Kingdom; orcid.org/0000-0002-0756-9764;
Phone: +441612471196; Email: c.banks@mmu.ac.uk
Nina C. Dempsey-Hibbert − Faculty of Science and
Engineering, Manchester Metropolitan University, Manchester
M1 5GD, United Kingdom; Phone: +441612471175;
Email: n.dempsey-hibbert@mmu.ac.uk
Authors
Robert D. Crapnell − Faculty of Science and Engineering,
Manchester Metropolitan University, Manchester M1 5GD,
United Kingdom
Whitchuta Jesadabundit − Electrochemistry and Optical
Spectroscopy Center of Excellence, Department of Chemistry,
Faculty of Science, Chulalongkorn University, Patumwan,
Bangkok 10330, Thailand
Alejandro García-Miranda Ferrari − Faculty of Science and
Engineering, Manchester Metropolitan University, Manchester
M1 5GD, United Kingdom
Marloes Peeters − Newcastle University, School of
Engineering, Newcastle Upon Tyne NE1 7RU, United
Kingdom; orcid.org/0000-0002-0429-8073
Ascanio Tridente − Intensive Care Unit, Whiston Hospital, St
Helens and Knowsley Teaching Hospitals NHS Trust, Prescot
L35 5DR, United Kingdom
Orawon Chailapakul − Electrochemistry and Optical
Spectroscopy Center of Excellence, Department of Chemistry,
Faculty of Science, Chulalongkorn University, Patumwan,
Bangkok 10330, Thailand
Complete contact information is available at:
https://pubs.acs.org/10.1021/acs.analchem.1c00417
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
A.G.-M.F. would like to acknowledge Innovate UK for funding
his Knowledge Transfer Partnership (KTP Reference: 11606).
■ REFERENCES
(1) Fleischmann, C.; Scherag, A.; Adhikari, N. K.; Hartog, C. S.;
Tsaganos, T.; Schlattmann, P.; Angus, D. C.; Reinhart, K. Am. J.
Respir. Crit. Care Med. 2016, 193 (3), 259−272.
(2) Kumar, A.; Roberts, D.; Wood, K. E.; Light, B.; Parrillo, J. E.;
Sharma, S.; Suppes, R.; Feinstein, D.; Zanotti, S.; Taiberg, L.; et al.
Crit. Care Med. 2006, 34 (6), 1589−1596.
(3) Singer, M.; Deutschman, C. S.; Seymour, C. W.; Shankar-Hari,
M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G. R.; Chiche, J.-D.;
Coopersmith, C. M.; et al. Jama 2016, 315 (8), 801−810.
(4) (a) Burki, T. K. Lancet Respir. Med. 2018, 6 (11), 826.
(b) Angurana, S. K.; Bansal, A.; Muralidharan, J.; Aggarwal, R.; Singhi,
S. Journal of Intensive Care Medicine 2020, 0885066620912989.
(c) Molano Franco, D. M.; Arevalo-Rodriguez, I.; i Figuls, M. R.;
Oleas, N. G. M.; Nuvials, X.; Zamora, J. Cochrane Database of
Systematic Reviews 2019, No. 4, CD011811. (d) Leal, Y. A.; Álvarez-
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